Hereditary breast cancer: Clinical features and risk reduction strategies

A. Paradiso, S. Formenti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Risk-reduction interventions for BRCA-related breast cancer are relevant not only for clinical decisions in breast cancer patients but also for healthy subjects who are potential candidates to undergo similar interventions. The literature on the impact of different surgical options and adjuvant systemic approaches aimed towards risk reduction for ipsilateral and contralateral breast cancer recurrences is briefly reviewed. Breast-conserving surgery is associated with a higher probability of local recurrence, but is counterbalanced by effectiveness of chemotherapy in reducing this risk. Consistent support for the hypothesis that antiestrogens are effective in reducing contralateral breast cancer risks is available from the literature. On the other hand, data on chemoprevention approaches for healthy subjects are too preliminary to draw any conclusions. Studies including conventional and newer hormonal drugs are needed to demonstrate the benefit of chemoprevention approaches. These may also deepen our knowledge on possible differences in the likelihood of clinical benefit to be expected among BRCA1- and BRCA2-altered tumours.

Original languageEnglish
JournalAnnals of Oncology
Volume22
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Risk Reduction Behavior
Breast Neoplasms
Chemoprevention
Healthy Volunteers
Recurrence
Estrogen Receptor Modulators
Segmental Mastectomy
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Hereditary breast cancer : Clinical features and risk reduction strategies. / Paradiso, A.; Formenti, S.

In: Annals of Oncology, Vol. 22, No. SUPPL. 1, 01.2011.

Research output: Contribution to journalArticle

@article{aa33ab01971c4428baa9cff85ad7e2ec,
title = "Hereditary breast cancer: Clinical features and risk reduction strategies",
abstract = "Risk-reduction interventions for BRCA-related breast cancer are relevant not only for clinical decisions in breast cancer patients but also for healthy subjects who are potential candidates to undergo similar interventions. The literature on the impact of different surgical options and adjuvant systemic approaches aimed towards risk reduction for ipsilateral and contralateral breast cancer recurrences is briefly reviewed. Breast-conserving surgery is associated with a higher probability of local recurrence, but is counterbalanced by effectiveness of chemotherapy in reducing this risk. Consistent support for the hypothesis that antiestrogens are effective in reducing contralateral breast cancer risks is available from the literature. On the other hand, data on chemoprevention approaches for healthy subjects are too preliminary to draw any conclusions. Studies including conventional and newer hormonal drugs are needed to demonstrate the benefit of chemoprevention approaches. These may also deepen our knowledge on possible differences in the likelihood of clinical benefit to be expected among BRCA1- and BRCA2-altered tumours.",
author = "A. Paradiso and S. Formenti",
year = "2011",
month = "1",
doi = "10.1093/annonc/mdq663",
language = "English",
volume = "22",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Hereditary breast cancer

T2 - Clinical features and risk reduction strategies

AU - Paradiso, A.

AU - Formenti, S.

PY - 2011/1

Y1 - 2011/1

N2 - Risk-reduction interventions for BRCA-related breast cancer are relevant not only for clinical decisions in breast cancer patients but also for healthy subjects who are potential candidates to undergo similar interventions. The literature on the impact of different surgical options and adjuvant systemic approaches aimed towards risk reduction for ipsilateral and contralateral breast cancer recurrences is briefly reviewed. Breast-conserving surgery is associated with a higher probability of local recurrence, but is counterbalanced by effectiveness of chemotherapy in reducing this risk. Consistent support for the hypothesis that antiestrogens are effective in reducing contralateral breast cancer risks is available from the literature. On the other hand, data on chemoprevention approaches for healthy subjects are too preliminary to draw any conclusions. Studies including conventional and newer hormonal drugs are needed to demonstrate the benefit of chemoprevention approaches. These may also deepen our knowledge on possible differences in the likelihood of clinical benefit to be expected among BRCA1- and BRCA2-altered tumours.

AB - Risk-reduction interventions for BRCA-related breast cancer are relevant not only for clinical decisions in breast cancer patients but also for healthy subjects who are potential candidates to undergo similar interventions. The literature on the impact of different surgical options and adjuvant systemic approaches aimed towards risk reduction for ipsilateral and contralateral breast cancer recurrences is briefly reviewed. Breast-conserving surgery is associated with a higher probability of local recurrence, but is counterbalanced by effectiveness of chemotherapy in reducing this risk. Consistent support for the hypothesis that antiestrogens are effective in reducing contralateral breast cancer risks is available from the literature. On the other hand, data on chemoprevention approaches for healthy subjects are too preliminary to draw any conclusions. Studies including conventional and newer hormonal drugs are needed to demonstrate the benefit of chemoprevention approaches. These may also deepen our knowledge on possible differences in the likelihood of clinical benefit to be expected among BRCA1- and BRCA2-altered tumours.

UR - http://www.scopus.com/inward/record.url?scp=79551643321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551643321&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq663

DO - 10.1093/annonc/mdq663

M3 - Article

C2 - 21285148

AN - SCOPUS:79551643321

VL - 22

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -